Insulet Q3 FY2026: revenue up 19.2%, EPS $2.03, $1 billion buyback
Insulet beat its own bar in Q3 FY2026: revenue of $842.0 million grew 19.6% in constant currency, above the 17.5%-19.5% guide, and adjusted EPS of $1.99 cleared the $1.6186 consensus. Read the quarter as a margin story — gross margin 75.1%, operating margin 22.5% — paired with a $1 billion buyback and a firmer full-year outlook. The one blemish: nine-month free cash flow fell to $211.7 million from $329.5 million.
1 · Expected vs. Actual
Free preview belowGAAP net income of $141.1 million worked out to $2.03 per diluted share, up from $1.24, and adjusted EPS of $1.99 came in about 22.9% above the $1.6186 consensus. The beat was operational, not accounting: operating income reached $189.8 million, or 22.5% of revenue, versus 16.7% a year earlier. Gross margin of 75.1%, up from 72.2%, did most of the heavy lifting.
Revenue of $842.0 million rose 19.2% from $706.3 million, and constant-currency growth of 19.6% landed just above the top of the 17.5%-19.5% range management had set. All of the growth came from Omnipod: product revenue of $836.6 million rose 19.7%, with International up 31.7% to $266.2 million against U.S. growth of 14.7% to $570.4 million. Drug Delivery, at $5.5 million, shrank 22.7% and is now a rounding error.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-04
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.